KRTAP4-7: A Potential Drug Target and Biomarker (G100132476)

Target Name: KRTAP4-7

NCBI ID: G100132476

KRTAP4-7

KRTAP4-7: A Potential Drug Target and Biomarker

Kr锟絘pipiravir (KRTAP) is a drug developed by Vertex Pharmaceuticals that is being investigated for the treatment of cystic fibrosis. This drug is a prototypical RNA-based inhibitor of RNA polymerase II, which is a key enzyme involved in the production of proteins in the cell. Cystic fibrosis is a genetic disease that affects the respiratory and digestive systems, and it is caused by mutations in the CFTR gene, which encodes a protein involved in the transport of chloride ions into and out of cells.

KRTAP4-7 is a gene that has been identified as a potential drug target and biomarker for cystic fibrosis. This gene is located on chromosome 16 and encodes a protein known as KRTAP4-7, which is a key regulator of the transport of chloride ions into and out of cells.

KRTAP4-7 is a 21-kDa protein that is expressed in many different tissues and cells in the body. It is involved in the regulation of the activity of the CFTR gene, which encodes the protein involved in cystic fibrosis. KRTAP4-7 has been shown to play a role in the regulation of the transport of chloride ions into and out of cells, which is thought to be important for the development and progression of cystic fibrosis.

KRTAP4-7 is also known as HTRT2, and it is a member of the HTRT family of proteins. This family of proteins is known for its role in the regulation of various cellular processes, including cell growth, differentiation, and DNA replication.

KRTAP4-7 has been shown to be involved in the regulation of the activity of the CFTR gene in a variety of cell types and tissues. For example, studies have shown that KRTAP4-7 can cause the CFTR gene to be expressed at higher levels in some cells than in others, which may be important for the development and progression of cystic fibrosis.

In addition to its role in the regulation of the CFTR gene, KRTAP4-7 has also been shown to be involved in the regulation of other genes and cellular processes. For example, studies have shown that KRTAP4-7 can cause the cell to enter a state of G1-cellular arrest, which is a type of cell cycle arrest that can be useful for the study of gene function and the development of cancer.

KRTAP4-7 has also been shown to be involved in the regulation of the production of various proteins in the cell. For example, studies have shown that KRTAP4-7 can cause the production of proteins involved in cell adhesion, migration, and invasion, which may be important for the development and progression of cystic fibrosis.

Overall, KRTAP4-7 is a gene that has been identified as a potential drug target and biomarker for cystic fibrosis. Its involvement in the regulation of the CFTR gene and its role in the regulation of various cellular processes and the production of proteins make it an attractive target for drug development. Further research is needed to fully understand the role of KRTAP4-7 in cystic fibrosis and to develop effective treatments.

Protein Name: Keratin Associated Protein 4-7

Functions: In the hair cortex, hair keratin intermediate filaments are embedded in an interfilamentous matrix, consisting of hair keratin-associated proteins (KRTAP), which are essential for the formation of a rigid and resistant hair shaft through their extensive disulfide bond cross-linking with abundant cysteine residues of hair keratins. The matrix proteins include the high-sulfur and high-glycine-tyrosine keratins

The "KRTAP4-7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KRTAP4-7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets